Publikace
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial2012 | 1. lékařská fakulta
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial2012 | 1. lékařská fakulta
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis2012 | 1. lékařská fakulta
- Interferon-beta or azathioprine as add-on therapies in patients with active multiple sclerosis2012 | 1. lékařská fakulta
- Fingolimod2011 | 1. lékařská fakulta
- Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies2024 | 1. lékařská fakulta
- Tract-wise microstructural analysis informs on current and future disability in early multiple sclerosis2024 | 1. lékařská fakulta
- Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom2024 | 1. lékařská fakulta
- Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries2023 | 1. lékařská fakulta, 3. lékařská fakulta, 2. lékařská fakulta, Lékařská fakulta v Hradci Králové, Lékařská fakulta v Plzni
- Is breastfeeding in MS harmful or not? An answer from real-world Czech data2023 | 1. lékařská fakulta, 3. lékařská fakulta, 2. lékařská fakulta, Lékařská fakulta v Hradci Králové, Lékařská fakulta v Plzni
Loading network view...